coagulation factor viii + von willebrand factor complex

**Coagulation factor VIII + von Willebrand factor complex** is a plasma-derived combination therapy that contains two noncovalently bound proteins—coagulation factor VIII and von Willebrand factor (VWF). The combination is used to treat and prevent bleeding episodes in individuals with von Willebrand disease (VWD, all types) and hemophilia A. **Mechanism of action:** VWF mediates binding between platelets and damaged endothelium, facilitating platelet adhesion and aggregation, and serves as a stabilizer and carrier for factor VIII. Factor VIII functions as an essential cofactor that, when activated, helps activate factor X, resulting in thrombin and fibrin formation necessary for clotting. The therapy temporarily raises levels of factor VIII and VWF in the blood to restore hemostasis. It is derived from pooled human plasma and undergoes viral inactivation steps to minimize transmissible disease risks. Major indications include bleed control, perioperative management, and bleed prophylaxis in VWD and hemophilia A[1][2][4][5][6].

Brand names

AlphanateHumate-PWilateWilfactinWilstartDried Factor VIII Fraction Type 8YHaemate POptivate

Other names

antihemophilic factor/von willebrand factor complexantihemophilic and von willebrand factor complexfactor viii / vwf complexvon willebrand factor and factor viii complex human